Readnour Robin Shane

CIK 00019148831 companyMENLO PARK, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001914883

Recent Transactions

34 trades

Award
AN2 Therapeutics, Inc.$ANTX
Stock Option (Right to Buy)
2026-02-20+20,400→ 20,400 total
Award
AN2 Therapeutics, Inc.$ANTX
Stock Option (Right to Buy)
2025-05-22+19,111→ 19,111 total
Award
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-12-19+9,077→ 9,077 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-12-10$1.49/sh+5,000→ 652,573 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-12-10$1.49/sh+5,000→ 582,288 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-12-09$1.43/sh+18,483→ 647,573 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-12-09$1.43/sh+12,289→ 577,288 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-12-06$1.45/sh+12,711→ 564,999 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-12-06$1.45/sh+6,517→ 629,090 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-11-27$1.42/sh+25,000→ 622,573 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-11-27$1.42/sh+25,000→ 552,288 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-11-26$1.39/sh+12,500→ 527,288 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-11-26$1.39/sh+12,500→ 597,573 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-11-20$1.16/sh+25,000→ 585,073 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-11-20$1.15/sh+25,000→ 514,788 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-11-19$1.03/sh+75,000→ 560,073 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-11-19$1.04/sh+75,000→ 489,788 total
Award
AN2 Therapeutics, Inc.$ANTX
Stock Option (Right to Buy)
2024-06-19+64,503→ 64,503 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-01-12$21.92/sh−706→ 414,788 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-01-12$21.91/sh−719→ 485,073 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-01-10$21.92/sh−1,800→ 485,792 total
Sale
AN2 Therapeutics, Inc.$ANTX
Common Stock
2024-01-10$21.93/sh−1,869→ 415,494 total
Award
AN2 Therapeutics, Inc.$ANTX
Stock Option (right to buy)
2023-06-07+23,742→ 23,742 total
Award
AN2 Therapeutics, Inc.$ANTX
Stock Option (right to buy)
2022-05-12+20,724→ 20,724 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29+61,491→ 346,647 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29+71,839→ 404,974 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29$15.00/sh+70,716→ 417,363 total
Purchase
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29$15.00/sh+82,618→ 487,592 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29+285,156→ 285,156 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Series A Convertible Preferred Stock
2022-03-29−333,135→ 0 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Series B Convertible Preferred Stock
2022-03-29−61,491→ 0 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Series B Convertible Preferred Stock
2022-03-29−71,839→ 0 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Series A Convertible Preferred Stock
2022-03-29−285,156→ 0 total
Conversion
AN2 Therapeutics, Inc.$ANTX
Common Stock
2022-03-29+333,135→ 333,135 total

Companies

AN2 Therapeutics, Inc.
Director
$ANTX

Recent Filings

Address

C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100

MENLO PARK, CA, 94025

View on SEC.gov